1800-272-662
Shopping Cart 0
countryflagAU
Login

Tempest Therapeutics Inc

Healthcare US TPST

2.37USD
-0.03(1.25%)

Last update at 2026-03-11T17:49:00Z

Day Range

2.372.43
LowHigh

52 Week Range

0.179.77
LowHigh

Fundamentals

  • Previous Close 2.40
  • Market Cap72.10M
  • Volume31305
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-28.77600M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.72

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -29.49100M -35.70900M -28.30200M -19.20800M -44.56800M
Minority interest - - - - -
Net income -29.49100M -36.77800M -29.55000M -19.11800M -44.56800M
Selling general administrative 11.66M 12.11M 9.82M 4.91M 5.51M
Selling and marketing expenses 0.38M - - - 16.50M
Gross profit -0.38100M -1.81400M -1.27000M -0.81500M -1.05200M
Reconciled depreciation 0.51M 0.64M 0.37M 0.34M -
Ebit -29.15700M -34.64000M -26.98600M -19.29800M -45.39900M
Ebitda -28.77600M -34.09100M -26.64600M -18.95900M -44.34700M
Depreciation and amortization 0.38M 0.55M 0.34M 0.34M 1.05M
Non operating income net other - - - - -
Operating income -29.15700M -34.64000M -26.98600M -19.29800M -45.39900M
Other operating expenses 29.16M 34.64M 26.99M 19.30M 45.40M
Interest expense 1.45M 1.62M 1.28M 0.51M 1.04M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M -
Interest income 1.10M 0.55M 0.07M 0.09M -
Net interest income -1.50400M -1.61800M -1.28200M 0.09M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 1.07M 1.25M -0.09000M 0.00100M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 28.78M 34.64M 26.99M 19.30M 44.35M
Cost of revenue 0.38M 1.81M 1.27M 0.81M 1.05M
Total other income expense net -0.33400M -1.06900M -1.31600M 0.09M 0.83M
Discontinued operations - - - - -
Net income from continuing ops -31.10600M -35.70900M -28.30200M -19.20800M -
Net income applicable to common shares - - -28.30200M -19.20800M -14.36500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 51.60M 46.09M 73.24M 22.86M 74.97M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.13M 1.27M 0.55M 0.06M 7.38M
Total liab 24.84M 27.98M 37.12M 91.66M 15.10M
Total stockholder equity 26.77M 18.11M 36.12M -68.79300M 58.55M
Deferred long term liab - - - - -
Other current liab 3.33M 4.76M 17.59M 1.44M 10.82M
Common stock 0.02M 0.01M 0.00700M 0.01M 0.02M
Capital stock 0.02M 0.01M 0.00700M 0.00100M -
Retained earnings -165.26300M -135.77200M -100.06300M -71.76100M -208.65400M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.11M 2.51M 0.05M
Cash 39.23M 31.23M 51.83M 18.82M 62.48M
Cash and equivalents - - - - -
Total current liabilities 9.41M 7.28M 20.03M 3.22M 12.52M
Current deferred revenue - - - - -
Net debt -18.56900M -9.11600M -33.29200M -16.38100M -62.10200M
Short term debt 5.24M 1.41M 1.44M 0.71M 0.21M
Short long term debt 4.29M - - - -
Short long term debt total 20.66M 22.11M 18.54M 2.44M 0.38M
Other stockholder equity 192.01M 153.87M 136.17M 2.50M 267.02M
Property plant equipment - - 4.16M 2.99M 3.75M
Total current assets 40.36M 32.95M 68.96M 19.82M 71.13M
Long term investments - - - - -
Net tangible assets - - 36.12M -68.79300M -50.36400M
Short term investments - - - - -
Net receivables - 0.45M 15.00M 0.26M 1.28M
Long term debt 6.26M 10.37M 15.07M - -
Inventory - - 1.58M 0.69M -
Accounts payable 0.84M 1.11M 0.99M 1.07M 1.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - -73.23800M 0.45M 0.17M
Additional paid in capital - - - - -
Common stock total equity - - - 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.06M 0.43M 0.11M 0.05M 0.51M
Deferred long term asset charges - - - - -
Non current assets total 11.24M 13.14M 4.28M 3.04M 3.84M
Capital lease obligations 10.11M 11.74M 3.47M 2.44M -
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.51900M -0.56200M -0.09700M -0.00600M -
Change to liabilities - - -0.20900M -0.57400M 0.95M
Total cashflows from investing activities - - -0.09700M -0.00600M -1.36400M
Net borrowings - - 15.00M 15.00M 15.00M
Total cash from financing activities 35.60M 11.40M 59.06M 34.60M 26.94M
Change to operating activities - - -0.40400M -0.49700M -0.26000M
Net income -29.49100M -35.70900M -28.30200M -19.20800M -44.56800M
Change in cash 8.00M -20.23100M 33.01M 15.58M -9.81900M
Begin period cash flow 31.23M 51.83M 18.82M 3.24M 73.33M
End period cash flow 39.23M 31.60M 51.83M 18.82M 63.51M
Total cash from operating activities -27.35700M -31.07200M -25.95700M -19.01700M -41.22200M
Issuance of capital stock 1.27M 16.14M 33.42M 35.00M -
Depreciation 0.38M 0.64M 0.37M 0.34M 1.05M
Other cashflows from investing activities - - 0.04M 0.04M 0.04M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.04M 7.28M 40.54M 34.60M 23.00M
Change to netincome - - 2.58M 0.92M -7.99200M
Capital expenditures 0.17M 0.56M 0.14M 0.05M 0.40M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.67700M 0.87M -0.61300M -1.07100M -2.05300M
Stock based compensation 2.55M 1.56M 1.10M 0.45M 0.31M
Other non cash items 5.46M 1.57M 1.48M 0.47M 6.92M
Free cash flow -27.52700M -31.63400M -26.09200M -19.06700M -41.61900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
TPST
Tempest Therapeutics Inc		 -0.03 1.25% 2.37 - - - 2.98 -2.2089
NVO
Novo Nordisk A/S		 0.05 0.13% 38.77 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -7.26 1.45% 491.91 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.47 0.84% 778.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Tempest Therapeutics Inc

2000 Sierra Point Parkway, Brisbane, CA, United States, 94005

Key Executives

Name Title Year Born
Mr. Stephen R. Brady J.D., LLM CEO & Director 1970
Dr. Thomas W. Dubensky Jr., Ph.D. Pres & Director 1958
Dr. Samuel Whiting M.D., Ph.D. Exec. VP & Chief Medical Officer NA
Mr. Nicholas Maestas VP of Strategy & Fin. and Sec. 1980
Mr. Justin Trojanowski Corp. Controller, Treasurer & Principal Accounting Officer 1988
Mr. Petpiboon Prasit Acting Chief Scientific Officer & Exec. Director NA
Dr. Sharon Sakai Ph.D., RAC Head of Regulatory & Quality NA
Dr. Anne Moon Sr. VP and Head of Project Team Leadership, Project Management & Portfolio Management NA
Mr. Stephen R. Brady J.D., LLM CEO, President & Director 1970
Dr. Samuel Whiting M.D., Ph.D. Executive VP & Chief Medical Officer 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.